-
Novavax CEO Talks $1.6B Federal Funding Win, Ex-FDA Chief Says It's A 'Good Bet'
Tuesday, July 7, 2020 - 10:48am | 466Read More...The U.S. government awarded Novavax, Inc. (NASDAQ: NVAX) $1.6 billion in funding to support its COVID-19 vaccine, and the company is confident it has the capability to produce 100 million doses by the end of the year, Novavax CEO Stanley Erck said on CNBC's "Squawk Box." Novavax...
-
Novavax Gets FDA's Fast Track Designation For Its RSV Vaccine For Older Adults
Wednesday, May 25, 2016 - 8:09am | 340Read More...Novavax, Inc. (NASDAQ: NVAX), a clinical-stage vaccine company, revealed Wednesday that the U.S. Food and Drug Administration has granted Fast Track Designation to its RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults. According to the company, an...
-
Novavax CEO To Jim Cramer: 'We Are In For An Exciting Year'
Wednesday, January 13, 2016 - 10:11am | 209Read More...Novavax, Inc. (NASDAQ: NVAX) CEO Stanley Erck was a guest on Jim Cramer's "Mad Money" segment on Tuesday. Novavax is a clinical stage-vaccine company that targets known and newly emerging diseases. Its stock has lost around 20 percent since the start of 2016 more than 50 percent...
